{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:52:07Z","timestamp":1783648327641,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS070899"],"award-info":[{"award-number":["R01NS070899"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35NS116824"],"award-info":[{"award-number":["R35NS116824"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01NS097197"],"award-info":[{"award-number":["P01NS097197"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.yebeh.2025.110654","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T11:47:35Z","timestamp":1756295255000},"page":"110654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The 9th annual Lafora science symposium: a rare epilepsy community makes progress towards clinical readiness"],"prefix":"10.1016","volume":"171","author":[{"given":"Meredith I.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine J.","family":"Donohue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascual","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souad","family":"Messahel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Serratosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Michelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Muccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Delgado-Escueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viet-Huong V.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berge A.","family":"Minassian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5253-9049","authenticated-orcid":false,"given":"Matthew S.","family":"Gentry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.yebeh.2025.110654_b0005","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/2470","article-title":"Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy","volume":"20","author":"Minassian","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.yebeh.2025.110654_b0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/hmg\/8.2.345","article-title":"A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2)","volume":"8","author":"Serratosa","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.yebeh.2025.110654_b0015","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/hmg\/4.9.1657","article-title":"The gene for progressive myoclonus epilepsy of the Lafora type maps to chromosome 6q","volume":"4","author":"Serratosa","year":"1995","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.yebeh.2025.110654_b0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/ng1238","article-title":"Mutations in NHLRC1 cause progressive myoclonus epilepsy","volume":"35","author":"Chan","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.yebeh.2025.110654_b0025","doi-asserted-by":"crossref","first-page":"30412","DOI":"10.1074\/jbc.M606117200","article-title":"Laforin, a dual specificity phosphatase that dephosphorylates complex carbohydrates","volume":"281","author":"Worby","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.yebeh.2025.110654_b0030","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1073\/pnas.0503285102","article-title":"Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin","volume":"102","author":"Gentry","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.yebeh.2025.110654_b0035","first-page":"606","article-title":"Lafora disease - from pathogenesis to treatment strategies","volume":"14","author":"Nitschke","year":"2018","journal-title":"Nat RevNeurol"},{"key":"10.1016\/j.yebeh.2025.110654_b0040","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13023-021-01989-w","article-title":"Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis","volume":"16","author":"Pondrelli","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.yebeh.2025.110654_b0045","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13023-023-02880-6","article-title":"Prognostic value of pathogenic variants in Lafora Disease: systematic review and meta-analysis of patient-level data","volume":"18","author":"Pondrelli","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.yebeh.2025.110654_b0050","article-title":"The 5th International Lafora Epilepsy Workshop: basic science elucidating therapeutic options and preparing for therapies in the clinic","volume":"103","author":"Gentry","year":"2020","journal-title":"EpilepsyBehav"},{"key":"10.1016\/j.yebeh.2025.110654_b0055","article-title":"The 6th International Lafora Epilepsy Workshop: advances in the search for a cure","volume":"119","author":"Markussen","year":"2021","journal-title":"EpilepsyBehav"},{"key":"10.1016\/j.yebeh.2025.110654_b0060","first-page":"284","article-title":"The 4th International Lafora Epilepsy Workshop: Shifting paradigms, paths to treatment, and hope for patients","volume":"90","author":"Brewer","year":"2019","journal-title":"EpilepsyBehav"},{"key":"10.1016\/j.yebeh.2025.110654_b0065","first-page":"125","article-title":"The 3rd International Lafora Epilepsy Workshop: evidence for a cure","volume":"81","author":"Brewer","year":"2018","journal-title":"EpilepsyBehav"},{"key":"10.1016\/j.yebeh.2025.110654_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117409","article-title":"Italian cohort of Lafora disease: clinical features, disease evolution, and genotype-phenotype correlations","volume":"424","author":"Riva","year":"2021","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.yebeh.2025.110654_b0075","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s13311-023-01434-9","article-title":"Gys1 antisense therapy prevents disease-driving aggregates and epileptiform discharges in a lafora disease mouse model","volume":"20","author":"Donohue","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.yebeh.2025.110654_b0080","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1093\/brain\/awab194","article-title":"Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease","volume":"144","author":"Ahonen","year":"2021","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.yebeh.2025.110654_b0085","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/genes15020171","article-title":"Progressive myoclonus epilepsy: a scoping review of diagnostic, phenotypic and therapeutic advances","volume":"15","author":"Zimmern","year":"2024","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.yebeh.2025.110654_b0090","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.ymgme.2018.12.211","article-title":"Safety and efficacy of VAL-1221, a novel fusion protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease","volume":"126","author":"Kishnani","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.yebeh.2025.110654_b0095","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-085062","article-title":"VAL-1221 for the treatment of patients with Lafora disease: study protocol for a single-arm, open-label clinical trial","volume":"14","author":"Muccioli","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.yebeh.2025.110654_b0100","first-page":"689","article-title":"Targeting pathogenic lafora bodies in lafora disease using an antibody-enzyme fusion","volume":"30","author":"Brewer","year":"2019","journal-title":"CellMetab"},{"key":"10.1016\/j.yebeh.2025.110654_b0105","doi-asserted-by":"crossref","unstructured":"Sun RC, Young LEA, Bruntz RC, Markussen KH, Zhou Z, Conroy LR, Hawkinson TR, Clarke HA, Stanback AE, Macedo JKA, Emanuelle S, Brewer MK, Rondon AL, Mestas A, Sanders WC, Mahalingan KK, Tang B, Chikwana VM, Segvich DM, Contreras CJ, Allenger EJ, Brainson CF, Johnson LA, Taylor RE, Armstrong DD, Shaffer R, Waechter CJ, Vander Kooi CW, DePaoli-Roach AA, Roach PJ, Hurley TD, Drake RR, Gentry MS. Brain glycogen serves as a critical glucosamine cache required for protein glycosylation. Cell Metab. 2021 Jul 6;33(7):1404-1417.e9. doi: 10.1016\/j.cmet.2021.05.003. Epub 2021 May 26. PMID: 34043942; PMCID: PMC8266748.","DOI":"10.1016\/j.cmet.2021.05.003"},{"key":"10.1016\/j.yebeh.2025.110654_b0110","doi-asserted-by":"crossref","unstructured":"Austin GL, Simmons ZR, Klier JE, Rondon A, Hodges BL, Shaffer R, Aziz NM, McKnight TR, Pauly JR, Armstrong DD, Vander Kooi CW, Gentry MS. Central Nervous System Delivery and Biodistribution Analysis of an Antibody-Enzyme Fusion for the Treatment of Lafora Disease. Mol Pharm. 2019 Sep 3;16(9):3791-3801. doi: 10.1021\/acs.molpharmaceut.9b00396. Epub 2019 Aug 2. PMID: 31329461; PMCID: PMC7189208.","DOI":"10.1021\/acs.molpharmaceut.9b00396"},{"key":"10.1016\/j.yebeh.2025.110654_b0115","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00109-017-1505-9","article-title":"Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease","volume":"95","author":"Yi","year":"2017","journal-title":"J Mol Med"},{"key":"10.1016\/j.yebeh.2025.110654_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2024.107317","article-title":"Effect of intracerebroventricular administration of alglucosidase alfa in two mouse models of Lafora disease: Relevance for clinical practice","volume":"200","author":"Zafra-Puerta","year":"2024","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2025.110654_b0125","article-title":"Gene replacement therapy for Lafora disease in the Epm2a -\/- mouse model","author":"Zafra-Puerta","year":"2023","journal-title":"BioRxiv"},{"key":"10.1016\/j.yebeh.2025.110654_b0130","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.ymthe.2024.05.032","article-title":"Gene therapy for Lafora disease in the Epm2a-\/- mouse model","volume":"32","author":"Zafra-Puerta","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.yebeh.2025.110654_b0135","doi-asserted-by":"crossref","unstructured":"Varea O, Guinovart JJ, Duran J. Malin restoration as proof of concept for gene therapy for Lafora disease. Brain Commun. 2022 Jun 23;4(4):fcac168. doi: 10.1093\/braincomms\/fcac168. PMID: 35813879; PMCID: PMC9260307.","DOI":"10.1093\/braincomms\/fcac168"},{"key":"10.1016\/j.yebeh.2025.110654_b0140","doi-asserted-by":"crossref","unstructured":"Varea O, Guinovart JJ, Duran J. Therapeutic Window for the Treatment of Lafora Disease. In: Noebels JL, Avoli M, Rogawski MA, Vezzani A, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies. 5th ed. New York: Oxford University Press; 2024. Chapter 53. PMID: 39637182.","DOI":"10.1093\/med\/9780197549469.003.0053"},{"key":"10.1016\/j.yebeh.2025.110654_b0145","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.7150\/thno.40902","article-title":"Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: Boosting the efficacy of intravenously administered therapeutic adenoviruses","volume":"10","author":"Brugada-Vil\u00e0","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.yebeh.2025.110654_b0150","doi-asserted-by":"crossref","DOI":"10.3390\/genes15010122","article-title":"Clinical signs in 166 Beagles with Different Genotypes of Lafora","volume":"15","author":"Flegel","year":"2024","journal-title":"Genes"},{"key":"10.1016\/j.yebeh.2025.110654_b0155","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1111\/jvim.16255","article-title":"A retrospective case series of clinical signs in 28 Beagles with Lafora disease","volume":"35","author":"Flegel","year":"2021","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.yebeh.2025.110654_b0160","doi-asserted-by":"crossref","unstructured":"Rubio T, Viana R, Moreno-Estell\u00e9s M, Campos-Rodr\u00edguez \u00c1, Sanz P. TNF and IL6\/Jak2 signaling pathways are the main contributors of the glia-derived neuroinflammation present in Lafora disease, a fatal form of progressive myoclonus epilepsy. Neurobiol Dis. 2023 Jan;176:105964. doi: 10.1016\/j.nbd.2022.105964. Epub 2022 Dec 14. PMID: 36526090; PMCID: PMC10682476.","DOI":"10.1016\/j.nbd.2022.105964"},{"key":"10.1016\/j.yebeh.2025.110654_b0165","article-title":"Glial alterations in the glutamatergic and GABAergic signaling pathways in a mouse model of Lafora disease, a severe form of progressive myoclonus epilepsy","volume":"51","author":"Viana","year":"2025","journal-title":"Neurophatology and Applied Neurobiology"},{"key":"10.1016\/j.yebeh.2025.110654_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2022.105376","article-title":"The role of Tumour Necrosis factor in neuroinflammation associated with Parkinson's disease and targeted therapies","volume":"158","author":"Amin","year":"2022","journal-title":"Neurochem Int"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110654_b0175","doi-asserted-by":"crossref","first-page":"7047","DOI":"10.1038\/s41598-020-63766-2","article-title":"Innate immune functions of astrocytes are dependent upon tumor necrosis factor-alpha","volume":"10","author":"Rodgers","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.yebeh.2025.110654_b0180","article-title":"Simultaneous monitoring of glycogen, creatine, and phosphocreatine in type II glycogen storage disease using saturation transfer MRI","author":"Bie","year":"2024","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.yebeh.2025.110654_b0185","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1073\/pnas.1909921117","article-title":"Magnetic resonance imaging of glycogen using its magnetic coupling with water","volume":"117","author":"Zhou","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.yebeh.2025.110654_b0190","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/ana.27054","article-title":"Population-based evidence for the use of serum neurofilaments as individual diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis","volume":"96","author":"Witzel","year":"2024","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2025.110654_b0195","doi-asserted-by":"crossref","unstructured":"Rajasekaran K, Ma Q, Good LB, Kathote G, Jakkamsetti V, Liu P, et al. Metabolic modulation of synaptic failure and thalamocortical hypersynchronization with preserved consciousness in Glut1 deficiency. Sci Transl Med. 2022 Oct 5;14(665):eabn2956. doi: 10.1126\/scitranslmed.abn2956. Epub 2022 Oct 5. PMID: 36197967; PMCID: PMC10276203.","DOI":"10.1126\/scitranslmed.abn2956"},{"key":"10.1016\/j.yebeh.2025.110654_b0200","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00401-024-02698-x","article-title":"Myofiber-type-dependent \u201cboulder\u201d or \u201cmultitudinous pebble\u201d formations across distinct amylopectinoses","volume":"147","author":"Mitra","year":"2024","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.yebeh.2025.110654_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00446","article-title":"Neurological glycogen storage diseases and emerging therapeutics","volume":"21","author":"Colpaert","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.yebeh.2025.110654_b0210","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/jnc.15926","article-title":"The multifaceted roles of the brain glycogen","volume":"168","author":"Markussen","year":"2024","journal-title":"J Neurochem"},{"key":"10.1016\/j.yebeh.2025.110654_b0215","doi-asserted-by":"crossref","unstructured":"Sun RC, Dukhande VV, Zhou Z, Young LEA, Emanuelle S, Brainson CF, Gentry MS. Nuclear Glycogenolysis Modulates Histone Acetylation in Human Non-Small Cell Lung Cancers. Cell Metab. 2019 Nov 5;30(5):903-916.e7. doi: 10.1016\/j.cmet.2019.08.014. Epub 2019 Sep 12. PMID: 31523006; PMCID: PMC6834909.","DOI":"10.1016\/j.cmet.2019.08.014"},{"key":"10.1016\/j.yebeh.2025.110654_b0220","doi-asserted-by":"crossref","unstructured":"Young LEA, Conroy LR, Clarke HA, Hawkinson TR, Bolton KE, Sanders WC, Chang JE, Webb MB, Alilain WJ, Vander Kooi CW, Drake RR, Andres DA, Badgett TC, Wagner LM, Allison DB, Sun RC, Gentry MS. In situ mass spectrometry imaging reveals heterogeneous glycogen stores in human normal and cancerous tissues. EMBO Mol Med. 2022 Nov 8;14(11):e16029. doi: 10.15252\/emmm.202216029. Epub 2022 Sep 5. PMID: 36059248; PMCID: PMC9641418.","DOI":"10.15252\/emmm.202216029"},{"key":"10.1016\/j.yebeh.2025.110654_b0225","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1038\/s41467-023-38437-1","article-title":"Spatial metabolomics reveals glycogen as an actionable target for pulmonary fibrosis","volume":"14","author":"Conroy","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.yebeh.2025.110654_b0230","doi-asserted-by":"crossref","unstructured":"Clarke HA, Hawkinson TR, Shedlock CJ, Medina T, Ribas RA, Wu L, Liu Z, Ma X, Xia Y, Huang Y, He X, Chang JE, Young LEA, Juras JA, Buoncristiani MD, James AN, Rushin A, Merritt ME, Mestas A, Lamb JF, Manauis EC, Austin GL, Chen L, Singh PK, Bian J, Vander Kooi CW, Evers BM, Brainson CF, Allison DB, Gentry MS, Sun RC. Glycogen drives tumour initiation and progression in lung adenocarcinoma. Nat Metab. 2025 Mar 11. doi: 10.1038\/s42255-025-01243-8. Epub ahead of print. PMID: 40069440.","DOI":"10.1038\/s42255-025-01243-8"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505025003944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505025003944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:22:35Z","timestamp":1778617355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505025003944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":46,"alternative-id":["S1525505025003944"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110654","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 9th annual Lafora science symposium: a rare epilepsy community makes progress towards clinical readiness","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110654","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110654"}}